COMPASS Pathways (CMPS) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

CMPS COMPASS Pathways

Watchlist

6.390
+0.120+1.91%

Close Oct 18 16:00 ET

6.298
-0.092-1.44%

Post 20:02 ET

437.00MMarket Cap-2852P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

FDA Is Said to See "Path Forward" for Ecstasy-based Drug
Seeking AlphaOct 19 09:40 ET
Express News | Compass Pathways PLC Files for Mixed Shelf of up to $400 Mln - SEC Filing
ReutersOct 7 08:21 ET
MDMA Therapy For PTSD Faces FDA Delay: Are There Other Ways Forward?
BenzingaSep 12 20:28 ET
RBC Capital Maintains COMPASS Pathways(CMPS.US) With Buy Rating, Maintains Target Price $23
Moomoo NewsSep 10 07:33 ET · Ratings
Compass Pathways to Participate in Three Investor Conferences in September
newsfilter.ioAug 28 06:00 ET
Galapagos, XPeng, CorMedix And Other Big Stocks Moving Higher On Monday
BenzingaAug 26 09:59 ET

Comments

IDKWTFIMDOING

Jul 22 04:21

$COMPASS Pathways (CMPS.US)$
https://www.fda.gov/news-events/press-announcements/fda-issues-first-draft-guidance-clinical-trials-psychedelic-drugs

Jaguar8

May 8 05:31

$COMPASS Pathways (CMPS.US)$
NEWS
Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorder

Jaguar8

May 2 06:00

$COMPASS Pathways (CMPS.US)$
NEWS
Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment

Moomoo AI

Jan 3 10:34

Cody Shandraw of Ambria Capital suggests FDA approval for MDMA legalization could be imminent, asserting that MDMA therapy might follow a similar trajectory to JNJ's Spravato treatment for depression. He is thrilled about the potential coverage of the therapy by the U.S. Department of Veterans Affairs for military personnel.